Intarcia Therapeutics is primed to file its potentially revolutionary diabetes drug delivery device after revealing positive cardiovascular safety results.
New drugs from Eli Lilly have produced a strong showing in the first quarter, in what could be a key year for a company still recovering from patent expiry of its former blockbuster antidep
